Clinical Trial Update: Assessment of Skin Lesions Using a Tissue Oxygen Imager Based on Protoporphyrin IX (PPIX) Fluorescence. This is an Open-label, Non-randomized, Feasibility Study That Includes a One-time Application of an FDA Approved Medication Followed by Local Imaging for Benign Skin Growth and Lesions Clinically

View source ↗

Summary

Open-label feasibility study assessing skin lesions with a tissue oxygen imaging method based on protoporphyrin IX fluorescence. It includes a one-time applicat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Benign Skin Growth
• Non-melanoma Skin Cancer

Snippet

Sponsor: Dartmouth-Hitchcock Medical Center | Conditions: Non-Melanoma Skin Cancer (NMSC), Benign Skin Growth | Status: RECRUITING